GBP1 and medical procedure: Then, to confirm this panel, we assessed the differential expression of lncRNA [SBF2-AS1 (SET binding factor 2 antisense RNA1) and FENDRR-19 (Fetal-lethal non-coding developmental regulatory RNA)] and mRNA [NLRP3 (NOD-like receptor and pyrin domain-containing 3) and GBP1 (guanylate-binding protein 1)] in the urine of renal stone patients treated with ESWL, then we compared with healthy volunteers to evaluate their usefulness as diagnostic biomarkers for post ESWL kidney injury.